FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2016323249> ?p ?o ?g. }

• W2016323249 endingPage "629" @default.
• W2016323249 startingPage "623" @default.
• W2016323249 abstract "Background Rituximab (RTX) has been shown to be effective and safe for short-term treatment of severe pemphigus. Its long-term results remain unknown. Objective We sought to evaluate long-term RTX efficacy and safety in comparison with classic immunosuppressants for the treatment of severe pemphigus. Methods This retrospective study included, from 1997 to 2010, 24 consecutive patients with severe pemphigus, treated with RTX (n = 13) or systemic corticosteroids alone or combined with immunosuppressants (n = 11 control subjects). Anti-desmoglein antibodies were titered by enzyme-linked immunosorbent assay, every 3 months the first year, then at least annually. Results Among the 13 patients treated with RTX, 9 achieved complete remission 3 months after a first RTX cycle. Thereafter, 7 patients (4 with maintenance therapy) relapsed within a mean of 18 months after the last RTX cycle and received 1 or 2 additional RTX cycles. With mean follow-up at 41 months after the first RTX cycle and 28 months after the last one, all 13 patients remained in complete remission (5 patients off therapy). No severe RTX side effects occurred. Anti-desmoglein-3 autoantibodies remained positive in 7 patients, despite long-term complete remission. Long-term remission rates and immunologic profiles did not differ between patients with pemphigus according to RTX status. Limitations This was a single-center, retrospective study. Conclusions RTX appeared to be an effective and well-tolerated treatment for severe pemphigus at long term. However, the long-term remission rate without maintenance therapy did not differ significantly from that of control subjects. Anti-desmoglein-1 autoantibody titers were more reliable than anti-desmoglein-3 titers for long-term follow-up. Rituximab (RTX) has been shown to be effective and safe for short-term treatment of severe pemphigus. Its long-term results remain unknown. We sought to evaluate long-term RTX efficacy and safety in comparison with classic immunosuppressants for the treatment of severe pemphigus. This retrospective study included, from 1997 to 2010, 24 consecutive patients with severe pemphigus, treated with RTX (n = 13) or systemic corticosteroids alone or combined with immunosuppressants (n = 11 control subjects). Anti-desmoglein antibodies were titered by enzyme-linked immunosorbent assay, every 3 months the first year, then at least annually. Among the 13 patients treated with RTX, 9 achieved complete remission 3 months after a first RTX cycle. Thereafter, 7 patients (4 with maintenance therapy) relapsed within a mean of 18 months after the last RTX cycle and received 1 or 2 additional RTX cycles. With mean follow-up at 41 months after the first RTX cycle and 28 months after the last one, all 13 patients remained in complete remission (5 patients off therapy). No severe RTX side effects occurred. Anti-desmoglein-3 autoantibodies remained positive in 7 patients, despite long-term complete remission. Long-term remission rates and immunologic profiles did not differ between patients with pemphigus according to RTX status. This was a single-center, retrospective study. RTX appeared to be an effective and well-tolerated treatment for severe pemphigus at long term. However, the long-term remission rate without maintenance therapy did not differ significantly from that of control subjects. Anti-desmoglein-1 autoantibody titers were more reliable than anti-desmoglein-3 titers for long-term follow-up." @default.
• W2016323249 created "2016-06-24" @default.
• W2016323249 creator A5004079103 @default.
• W2016323249 creator A5011728010 @default.
• W2016323249 creator A5014379743 @default.
• W2016323249 creator A5021234891 @default.
• W2016323249 date "2012-10-01" @default.
• W2016323249 modified "2023-10-05" @default.
• W2016323249 title "Rituximab treatment of severe pemphigus: Long-term results including immunologic follow-up" @default.
• W2016323249 cites W1971386513 @default.
• W2016323249 cites W1973903141 @default.
• W2016323249 cites W1975962822 @default.
• W2016323249 cites W2002134608 @default.
• W2016323249 cites W2006779897 @default.
• W2016323249 cites W2007663198 @default.
• W2016323249 cites W2010282370 @default.
• W2016323249 cites W2015284085 @default.
• W2016323249 cites W2020339964 @default.
• W2016323249 cites W2022345441 @default.
• W2016323249 cites W2031001939 @default.
• W2016323249 cites W2032628179 @default.
• W2016323249 cites W2040876247 @default.
• W2016323249 cites W2047471137 @default.
• W2016323249 cites W2050148011 @default.
• W2016323249 cites W2053684390 @default.
• W2016323249 cites W2063470653 @default.
• W2016323249 cites W2064997042 @default.
• W2016323249 cites W2065526075 @default.
• W2016323249 cites W2074088798 @default.
• W2016323249 cites W2076802877 @default.
• W2016323249 cites W2092254784 @default.
• W2016323249 cites W2110332942 @default.
• W2016323249 cites W2120741582 @default.
• W2016323249 cites W2122715855 @default.
• W2016323249 cites W2135749720 @default.
• W2016323249 cites W2317276018 @default.
• W2016323249 doi "https://doi.org/10.1016/j.jaad.2011.12.019" @default.
• W2016323249 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22261417" @default.
• W2016323249 hasPublicationYear "2012" @default.
• W2016323249 type Work @default.
• W2016323249 sameAs 2016323249 @default.
• W2016323249 citedByCount "56" @default.
• W2016323249 countsByYear W20163232492012 @default.
• W2016323249 countsByYear W20163232492013 @default.
• W2016323249 countsByYear W20163232492014 @default.
• W2016323249 countsByYear W20163232492015 @default.
• W2016323249 countsByYear W20163232492016 @default.
• W2016323249 countsByYear W20163232492017 @default.
• W2016323249 countsByYear W20163232492018 @default.
• W2016323249 countsByYear W20163232492019 @default.
• W2016323249 countsByYear W20163232492020 @default.
• W2016323249 countsByYear W20163232492021 @default.
• W2016323249 countsByYear W20163232492022 @default.
• W2016323249 crossrefType "journal-article" @default.
• W2016323249 hasAuthorship W2016323249A5004079103 @default.
• W2016323249 hasAuthorship W2016323249A5011728010 @default.
• W2016323249 hasAuthorship W2016323249A5014379743 @default.
• W2016323249 hasAuthorship W2016323249A5021234891 @default.
• W2016323249 hasConcept C126322002 @default.
• W2016323249 hasConcept C141071460 @default.
• W2016323249 hasConcept C159654299 @default.
• W2016323249 hasConcept C163764329 @default.
• W2016323249 hasConcept C167135981 @default.
• W2016323249 hasConcept C203014093 @default.
• W2016323249 hasConcept C2776694085 @default.
• W2016323249 hasConcept C2778283404 @default.
• W2016323249 hasConcept C2779338263 @default.
• W2016323249 hasConcept C2780653079 @default.
• W2016323249 hasConcept C2781313415 @default.
• W2016323249 hasConcept C2781327288 @default.
• W2016323249 hasConcept C2910519024 @default.
• W2016323249 hasConcept C3018657049 @default.
• W2016323249 hasConcept C71924100 @default.
• W2016323249 hasConcept C90924648 @default.
• W2016323249 hasConceptScore W2016323249C126322002 @default.
• W2016323249 hasConceptScore W2016323249C141071460 @default.
• W2016323249 hasConceptScore W2016323249C159654299 @default.
• W2016323249 hasConceptScore W2016323249C163764329 @default.
• W2016323249 hasConceptScore W2016323249C167135981 @default.
• W2016323249 hasConceptScore W2016323249C203014093 @default.
• W2016323249 hasConceptScore W2016323249C2776694085 @default.
• W2016323249 hasConceptScore W2016323249C2778283404 @default.
• W2016323249 hasConceptScore W2016323249C2779338263 @default.
• W2016323249 hasConceptScore W2016323249C2780653079 @default.
• W2016323249 hasConceptScore W2016323249C2781313415 @default.
• W2016323249 hasConceptScore W2016323249C2781327288 @default.
• W2016323249 hasConceptScore W2016323249C2910519024 @default.
• W2016323249 hasConceptScore W2016323249C3018657049 @default.
• W2016323249 hasConceptScore W2016323249C71924100 @default.
• W2016323249 hasConceptScore W2016323249C90924648 @default.
• W2016323249 hasIssue "4" @default.
• W2016323249 hasLocation W20163232491 @default.
• W2016323249 hasLocation W20163232492 @default.
• W2016323249 hasOpenAccess W2016323249 @default.
• W2016323249 hasPrimaryLocation W20163232491 @default.
• W2016323249 hasRelatedWork W112917578 @default.
• W2016323249 hasRelatedWork W1519598920 @default.
• W2016323249 hasRelatedWork W1967938091 @default.

• next